PAVmed Inc expected to post a loss of 57 cents a share - Earnings Preview

PAVmed

21/03/2025 20:11

PAVmed Inc PAVM.OQ PAVM.O is expected to show a fall in quarterly revenue when it reports  results on March 24 for the period ending December 31 2024

The New York City-based  company is expected to report a 44.7% decrease in revenue to $580 thousand from $1.05 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

‚ÄčLSEG's mean analyst estimate for PAVmed Inc is for a loss of 57 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ‚Äč

Wall Street's median 12-month price target for PAVmed Inc is $4.00‚Äč, above‚Äč its last closing price of $0.77. ‚Äč‚Äč‚Äč

Previous quarterly performance (using preferred earnings measure in US dollars). ‚Äč

QUARTER ENDING
STARMINESMARTESTIMATE¬ģ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
2.29
1.98
1.44
Missed
-27.1
Jun. 30 2024
-1.48
-1.45
-1.19
Beat
18.1
Mar. 31 2024
-1.77
-1.67
-2.62
Missed
-56.6‚Äč
Dec. 31 2023
-1.47
-1.89
-1.81
Beat
4.2
‚Äč‚ÄčSep. 30 2023
-2.04
-2.05
-2.40
Missed
-17.1
Jun. 30 2023
-2.84
-2.85
-2.10
Beat
26.3‚Äč
Mar. 31 2023
-3.11
-3.10
-2.85
Beat
8.1
Dec. 31 2022
-3.84
-3.80
-3.45
Beat
9.2

This summary was machine generated March 21 at 20:11 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)